Advertisement
Screener

Celldex Therapeutics, Inc. (CLDX) Deferred Revenue Recognized

2.8 / 5 stars · 68/120 Roast Me

Celldex Therapeutics, Inc. Deferred Revenue Recognized

Celldex Therapeutics, Inc. (CLDX) reported Deferred Revenue Recognized of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Other Income

us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-06

  • Celldex Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $0.00.
  • Celldex Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $200.00K.
  • Celldex Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
  • Celldex Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2022-09-30 was $200.00K.
  • Celldex Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2024 was $3.10M, a 3000.00% increase from fiscal 2023.
  • Celldex Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $100.00K, a 75.00% decline from fiscal 2022.
  • Celldex Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was $400.00K, a 88.24% decline from fiscal 2021.
  • Celldex Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2021 was $3.40M, a 1600.00% increase from fiscal 2020.
Period endContract with Customer, Liability, Revenue Recognized 3 monthContract with Customer, Liability, Revenue Recognized 6 monthContract with Customer, Liability, Revenue Recognized 9 monthContract with Customer, Liability, Revenue Recognized 12 month
2026-06-30$0.00
10-Q · filed 2026-08-06
2026-03-31$0.00
10-Q · filed 2026-05-07
2024-12-31$3.10M
10-K · filed 2025-02-27
2024-09-30$2.80M
10-Q · filed 2024-11-06
2024-06-30$300.00K
10-Q · filed 2024-08-08
2024-03-31$200.00K
10-Q · filed 2024-05-06
2023-12-31$100.00K
10-K · filed 2024-02-26
2023-06-30$100.00K
10-Q · filed 2023-08-08
2023-03-31$0.00
10-Q · filed 2023-05-04
2022-12-31$400.00K
10-K · filed 2023-02-28
2022-09-30$200.00K
10-Q · filed 2022-11-09
$400.00K
10-Q · filed 2022-11-09
2022-06-30$100.00K
10-Q · filed 2022-08-08
$200.00K
10-Q · filed 2022-08-08
2022-03-31$100.00K
10-Q · filed 2022-05-05
2021-12-31$3.40M
10-K · filed 2022-02-28
2021-09-30$0.00
10-Q · filed 2021-11-09
$3.40M
10-Q · filed 2021-11-09
2021-06-30$3.00M
10-Q · filed 2021-08-05
$3.40M
10-Q · filed 2021-08-05
2021-03-31$400.00K
10-Q · filed 2021-05-06
2020-12-31$200.00K
10-K · filed 2021-03-29
2020-09-30$0.00
10-Q · filed 2020-11-05
$200.00K
10-Q · filed 2020-11-05
2020-06-30$0.00
10-Q · filed 2020-08-06
$100.00K
10-Q · filed 2020-08-06
2020-03-31$100.00K
10-Q · filed 2020-05-06
2019-12-31$1.40M
10-K · filed 2020-03-26
2019-09-30$100.00K
10-Q · filed 2019-11-12
$1.30M
10-Q · filed 2019-11-12
2019-06-30$400.00K
10-Q · filed 2019-08-07
$1.20M
10-Q · filed 2019-08-07
2019-03-31$800.00K
10-Q · filed 2019-05-07
2018-12-31$1.90M
10-K · filed 2019-03-07
2018-09-30$0.00
10-Q · filed 2018-11-07
$1.50M
10-Q · filed 2018-11-07
2018-06-30$1.00M
10-Q · filed 2018-08-08
$1.50M
10-Q · filed 2018-08-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEOGEN CORP (NEOG)United States$2.979B-247.49
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93